Trial Profile
Ipilimumab and Nivolumab in Combination With Immunoembolization for the Treatment of Metastatic Uveal Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Liver metastases; Uveal melanoma
- Focus Therapeutic Use
- 25 Mar 2024 Planned End Date changed from 30 Dec 2023 to 31 Dec 2024.
- 14 Nov 2023 Planned End Date changed from 30 Jun 2023 to 30 Dec 2023.
- 15 Aug 2022 Planned End Date changed from 1 Dec 2021 to 30 Jun 2023.